BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy (RRSO) should preferably have the procedure performed by which age to optimally reduce ovarian cancer risk?

• A 35 years for BRCA1, 40 years for BRCA2
• B 50 years for both BRCA1 and BRCA2
• C After completion of family, regardless of age
• D 40 years for BRCA1, 45 years for BRCA2 ✓

Explanation

Current guidelines recommend RRSO at approximately 40 years for BRCA1 carriers (higher risk, earlier age of ovarian cancer onset) and 45 years for BRCA2 carriers (later onset). RRSO reduces ovarian/fallopian tube cancer risk by approximately 80–96% and also confers a breast cancer risk reduction in pre-menopausal women. The procedure should follow completion of childbearing, but the age thresholds reflect the differing cancer onset profiles between BRCA1 and BRCA2.

Reference: Shaw's Textbook of Gynaecology, 17th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.